Neutral
Asset Management One Co. Ltd. significantly reduced its stake in Revvity Inc. (NYSE:RVTY) by 90.1% in the fourth quarter, selling 46,513 shares and re...
Neutral
Revvity Inc. (US76155R1086) provides tools for drug discovery and diagnostics, positioning it in the life sciences sector with robust demand. The comp...
Revvity recently launched new AI-enabled oncology platform tools and molecular cloning software, Signals BioDesign, aimed at streamlining cancer and b...
Neutral
Analysts project Revvity will report $1.02 EPS for Q1 2026, marking a slight increase year-over-year, with the company consistently exceeding Wall Str...
Bullish
Revvity Inc. has launched Signals BioDesign, a cloud-native molecular cloning solution designed to streamline biologics research workflows. This platf...